TY - JOUR ID - 142776 TI - COVID-19 Screening in Rheumatologic Diseases Cases; Special Look at Chloroquine Derivate Use JO - Hospital Practices and Research JA - HPR LA - en SN - 2476-390X AU - Shadmanfar, Soraya AU - Alishiri, Gholamhosein AU - Bayat, Noushin AU - Izadi, Morteza AU - Salimzadeh, Ahmad AU - Rostamian, Abdolrahman AU - Abolghasemi, Shahla AU - Azimzadeh Ardebili, Mohammad Hossein AU - Rastgar Moqaddam, Zeynab AU - Hasani, Marjan AU - Rahmanian, Ehsan AU - Iranpanah, Helia AU - Islami, Ghodrat Allah AU - Saburi, Amin AD - Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran AD - Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran AD - Exercise Physiology Research Center, Life Style Institute, Baqyiatallah University of Medical Sciences, Tehran, Iran AD - Sina Hospital, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran AD - Department of Rheumatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran AD - Department of Rheumatology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran AD - Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran AD - Iran University of Medical Science, Tehran, Iran AD - Shahid Beheshti University of Medical Sciences, Tehran, Iran Y1 - 2021 PY - 2021 VL - 6 IS - 4 SP - 141 EP - 147 KW - Angiotensin-converting enzyme inhibitors KW - Angiotensin II Type 1 Receptor Blockers KW - chloroquine KW - hydroxychloroquine KW - COVID-19 DO - 10.34172/hpr.2021.27 N2 - Background: Among suggested medications for the treatment of COVID-19, chloroquine derivates and angiotensin-converting–enzyme inhibitors (ACEIs)/angiotensin II type 1 receptor blockers (ARBs) are the two medications with conflicting effects on the development of the disease.Objectives: The present study aimed to evaluate COVID-19 in patients with rheumatic diseases receiving chloroquine derivate.Methods: Every patient with proven rheumatologic diseases registered in two referral centers in Tehran and Alborz, Iran was enrolled in the present descriptive cross-sectional study between May and June 2020. At first, the symptoms of COVID-19 were assessed, and if a case had suspicious symptoms, reverse transcription-polymerase chain reaction (RT-PCR) COVID-19 tests were done. Demographic and clinical data are documented for every patient. Then, the patients were grouped once according to their COVID-19 infection status and another time according to their hydroxychloroquine use.Results: 1159 patients enrolled in the study with a mean age of 49.39 years. Frequency of hypertension was 22.17 %, diabetics (9.49%) and 20 (1.7%) patients were positive for COVID-19 testing. The most common symptoms of the COVID-19 positive cases were cough (5.2%) and fever (4%). There was no significant difference in receiving ACEIs/ARBs or other medications between COVID-19 positive or negative patients. Among the patients receiving hydroxychloroquine, 15 patients (1.7%) had proved COVID-19 versus 5 patients (1.7%) who were not receiving these medications (P>0.999).Conclusion: The present study demonstrated that receiving ARBs or ACEIs was not different among patients with or without COVID-19. Moreover, receiving chloroquine derivate was not related to the development of COVID-19 in patients with rheumatologic disorders. UR - https://www.jhpr.ir/article_142776.html L1 - https://www.jhpr.ir/article_142776_3da6163bd8e661e555cd8da95f24cbcb.pdf ER -